Yale's Craig Crews Builds Model to Guide Biotech Startups Out of Academia's 'Valley of Death' on March 05, 2026 biotech startups Craig Crews Halda Therapeutics Pitch - substance Protein Degradation, Metabolic valley of death Yale +
Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion to Add RIPTAC Cancer Drug Platform on November 17, 2025 acquisition clinical pipeline Halda Therapeutics HLD-0915 Johnson & Johnson Malignant neoplasm of prostate Neoplasms RIPTAC Targeted Protein Degradation +
Halda’s HLD-0915 Shows Promising First-in-Human Results as a Safer RIPTAC Cancer Therapeutic on October 27, 2025 anti-tumor activity first-in-human Halda Therapeutics HLD-0915 Metastatic castration-resistant prostate cancer Oral cavity RIPTAC Safety +
Halda’s HLD-0915 Shows Promising First-in-Human Results as a Safer RIPTAC Cancer Therapeutic on October 27, 2025 anti-tumor activity first-in-human Halda Therapeutics HLD-0915 Metastatic castration-resistant prostate cancer Oral cavity RIPTAC Safety +
VantAI and Halda Strike $1B+ AI-Driven Partnership on 'Hold-and-Kill' Drugs on August 19, 2025 Artificial Intelligence cellular targeting Chimera organism Drug Discovery Halda Therapeutics hold-and-kill Immunology Induce (action) Neoplasms Proximity RIPTAC target-effector pairs VantAI +